REDWOOD CITY, Calif. and WALTHAM, Mass., Jan. 23, 2024 /PRNewswire/ -- Synthego, a leading provider of genome engineering solutions, and SeQure Dx, a company focused on off-target analysis for preclinical and clinical gene modification customers, have announced a strategic partnership to provide CRISPR-based therapeutics developers with comprehensive off-target editing analytical services that include best-in-class technology and turn-key end-to-end development solutions..

加利福尼亚州红木市和马萨诸塞州沃尔瑟姆，2024年1月23日/PRNewswire/--基因组工程解决方案的领先供应商Synthego和专注于临床前和临床基因修饰客户脱靶分析的SeQure Dx，已宣布建立战略合作伙伴关系，为基于CRISPR的治疗开发人员提供全面的脱靶编辑分析服务，其中包括一流的技术和全套端到端开发解决方案。。

This partnership furthers Synthego's mission to empower therapeutics developers by offering access to a comprehensive solution for every phase of CRISPR-based therapeutic development and connects SeQure Dx's portfolio of off-target technologies with Synthego's unique continuum of synthetic RUO-to-GMP guide RNAs, industry-leading regulatory expertise for CRISPR-based therapeutics, and extensive commercial infrastructure.

这种合作关系进一步促进了Synthego的使命，即通过为基于CRISPR的治疗开发的每个阶段提供全面的解决方案来增强治疗开发人员的能力，并将SeQure Dx的脱靶技术组合与Synthego独特的合成RUO连续体连接到GMP指导RNA，这是基于CRISPR的治疗的行业领先监管专业知识，以及广泛的商业基础设施。

The pairing of these capabilities ensures that more gene editing companies will have access to gold-standard assays to safely develop potentially life-saving therapeutics..

这些能力的结合确保了更多的基因编辑公司将获得金标准检测方法，以安全地开发潜在的挽救生命的疗法。。

The cornerstone of SeQure's platform highlighted in this new offering is the ONE-seq assay, a technology developed by Keith Joung and his lab at Massachusetts General Hospital. Through this unique partnership, therapeutic developers can achieve a more streamlined and efficient therapeutic development process, working with a single provider for both their synthetic gRNA solutions and off-target analyses, reducing the risk of errors and delays and providing the most comprehensive off-target identification solution available..

在这项新产品中，SeQure平台的基石是ONE-seq分析，这项技术是由基思·琼（KeithJoung）和他在马萨诸塞州总医院（Massachusetts General Hospital）的实验室开发的。通过这种独特的合作关系，治疗开发人员可以实现更简化和高效的治疗开发过程，与单一供应商合作进行合成gRNA解决方案和脱靶分析，降低错误和延迟的风险，并提供最全面的脱靶识别解决方案。。

'We are excited to partner with SeQure Dx to provide our customers with a comprehensive solution for their CRISPR-based therapeutic development needs,' says Eleanor Kolossovski, Synthego Vice President of Commercial. 'This partnership aligns with our mission to empower researchers and developers with the tools and resources they need to bring safe and efficacious therapies to patients.'.

Synthego商业副总裁埃莉诺·科洛索夫斯基（EleanorKolossovski）说：“我们很高兴与SeQure Dx合作，为客户提供全面的解决方案，满足他们基于CRISPR的治疗开发需求。”这种合作关系符合我们的使命，即为研究人员和开发人员提供为患者带来安全有效治疗所需的工具和资源。”。

SeQure Dx's ONE-seq technology is the most sensitive and the only universal off-target nomination method available that can account for the impacts of genetic variability at scale. Access to this unique capability ensures that investigators can have a more accurate and comprehensive understanding of off-target effects, informing internal strategic pipeline decisions, reducing regulatory risk, and improving the overall safety of their therapeutic products..

SeQure Dx的ONE-seq技术是最敏感且唯一可用的通用脱靶提名方法，可以解释大规模遗传变异的影响。使用这种独特的功能可以确保研究人员能够更准确和全面地了解脱靶效应，为内部战略管道决策提供信息，降低监管风险，并提高其治疗产品的整体安全性。。

'SeQure's best-in-class off-target nomination assays and confirmation platforms will seamlessly complement Synthego's end-to-end CRISPR-based portfolio of products and services,' says SeQure Dx founder Keith Joung. 'This partnership should provide CRISPR-focused therapeutics developers with access to an all-in-one solution for their preclinical and clinical needs.'.

SeQure Dx创始人基思·琼（KeithJoung）说：“SeQure一流的脱靶提名分析和确认平台将无缝补充Synthego基于CRISPR的端到端产品和服务组合。”这种合作关系应该为以CRISPR为重点的治疗药物开发人员提供一种针对其临床前和临床需求的一体化解决方案。”。

Regulatory agencies consider off-target analysis critical for developing therapeutic products, making this partnership a valuable asset for researchers and developers. Synthego has supported 16 IND submissions, of which 8 have been approved by the FDA, underscoring Synthego's commitment to understanding, interpreting, and addressing the evolving regulatory guidelines for CRISPR therapeutics developers during and after the IND submission process.

监管机构认为脱靶分析对于开发治疗产品至关重要，使这种合作关系成为研究人员和开发人员的宝贵资产。Synthego支持了16份IND提交，其中8份已获得FDA批准，强调了Synthego在IND提交过程中和之后对理解，解释和解决CRISPR治疗开发人员不断发展的监管指南的承诺。

With Synthego and SeQure Dx's combined expertise and resources, therapeutic developers can have greater confidence in the safety and efficacy of their CRISPR-based therapies throughout development..

凭借Synthego和SeQure Dx的综合专业知识和资源，治疗开发人员可以在整个开发过程中对其基于CRISPR的疗法的安全性和有效性更有信心。。

For more information on Synthego and SeQure Dx's partnership and offerings, please visit Synthego.com/off-target-editing-analysis.

有关Synthego和SeQure Dx合作伙伴关系和产品的更多信息，请访问Synthego.com/off-target-editing-analysis。

About Synthego:

关于Synthego：

Synthego is a pioneering provider of genome engineering solutions, offering a comprehensive suite of products and services to accelerate CRISPR-based cell and gene therapy development. With a commitment to empowering researchers and innovators, Synthego's cutting-edge technologies and expertise drive progress from preclinical to clinical application.

Synthego是基因组工程解决方案的先驱供应商，提供全面的产品和服务，以加速基于CRISPR的细胞和基因治疗的发展。Synthego致力于赋予研究人员和创新者权力，其尖端技术和专业知识推动了从临床前到临床应用的进步。

To learn more, visit synthego.com..

要了解更多信息，请访问synthego.com。。

About SeQure Dx:

关于SeQure Dx：

SeQure Dx is a genomics intelligence company dedicated to the advancement of gene editing and cell therapies from discovery to patient. SeQure's initial preclinical platforms for the biopharma industry, NoteSeQ and ScopeSeQ, comprise a suite of proprietary, best-in-class diagnostic assays and bioinformatic analytics that span the spectrum of off-target nomination and confirmation.

SeQure Dx是一家基因组学情报公司，致力于从发现到患者的基因编辑和细胞疗法的发展。SeQure最初的生物制药行业临床前平台NoteSeQ和ScopeSeQ包括一套专有的一流诊断分析和生物信息学分析，涵盖了脱靶提名和确认的范围。

The NoteSeQ and ScopeSeQ platforms comprehensively solve our partners' preclinical off-target evaluation needs, including guide selection and IND submissions. SeQure Dx's goal is to help ensure that gene editing and cell therapies are developed for all patients who would benefit from this next generation of life-saving technologies.

NoteSeQ和ScopeSeQ平台全面解决了我们合作伙伴的临床前脱靶评估需求，包括指南选择和IND提交。SeQure Dx的目标是帮助确保为所有将受益于下一代救生技术的患者开发基因编辑和细胞疗法。

For more information, please visit sequre-dx.com..

有关更多信息，请访问sequre dx.com。。

SOURCE Synthego

源Synthego